Company intelligence / Profile preview

Sagitta Biotech

Gosselies*, Wallonia, Belgiumsagittabiotech.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Sagitta Biotech has demonstrated in animal models that its active virosome-based influenza vaccine generates robust immune responses with no side effects and protects against infection. The company is seeking funding (€15–20 million) to initiate first-in-human clinical studies. The platform is designed for rapid adaptation to new pathogens or cancer targets and enables cost-effective manufacturing suitable for global health needs.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Viral vectors (active virosomes based on modified measles virus)Hybrid RNA/viral vector platform
Industry: Biotech

Drug pipeline

1 asset

RS-0139

Phase 1

Indications: Non-small cell lung cancer

Partnerships

Open to co-development with biotech/pharma partnersIncluded in an American incubator program

Beyond the preview

Go deeper on Sagitta Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sagitta Biotech.

Explore the full profile